C07K 2317/53
Hinge
C07K2317/53 (Hinge) appears on 1,055 US grants and 2,261 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,055
- Published applications
- 2,261
- Assignees
- 709
- Inventors
- 3,919
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 2 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 0 |
| 2003 | 2 | 6 |
| 2004 | 2 | 3 |
| 2005 | 1 | 24 |
| 2006 | 3 | 11 |
| 2007 | 4 | 16 |
| 2008 | 2 | 10 |
| 2009 | 6 | 33 |
| 2010 | 17 | 29 |
| 2011 | 14 | 35 |
| 2012 | 12 | 34 |
| 2013 | 20 | 62 |
| 2014 | 32 | 66 |
| 2015 | 46 | 63 |
| 2016 | 53 | 116 |
| 2017 | 41 | 133 |
| 2018 | 62 | 111 |
| 2019 | 74 | 124 |
| 2020 | 80 | 167 |
| 2021 | 87 | 208 |
| 2022 | 98 | 200 |
| 2023 | 94 | 196 |
| 2024 | 115 | 219 |
| 2025 | 118 | 219 |
| 2026 | 69 | 175 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Compositions and methods for treating cancer6 Oct 2026US 12,753,236 B2Alpha Beta Holdings, LLC
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Cd3 binding molecules8 Oct 2026US 2026/0308254 A1Merus N.V.
- Il12rb2 binding molecules and methods of use8 Oct 2026US 2026/0308265 A1Synthekine, Inc.
- Engineered Antibodies and Uses Thereof8 Oct 2026US 2026/0308277 A1Invitrogen Bioservices India Private Limited
- Chimeric engulfment receptor molecules and methods of use8 Oct 2026US 2026/0308281 A1Cero Therapeutics Holdings, Inc.
Most cited
By later US patents
- Recombinant production of immunoglobulin-like domains in prokaryotic cells477US 6,165,745 ABoard of Regents, The University of Texas System · 2000
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Molecules with extended half-lives, compositions and uses thereof342US 7,083,784 B2MedImmune, LLC · 2006
- Anti-PD1 antibodies and their use as therapeutics and diagnostics285US 8,735,553 B1BeiGene, Ltd. · 2014
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014